Eswari Vilayur

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

The Association Between Reduced GFR and Hearing Loss: A Cross-sectional Population-Based Study

Eswari Vilayur, Bamini Gopinath, David C.H. Harris et al. · American Journal of Kidney Diseases · 2010 · 91 citations

Family Medicine, Health Sciences, Cross-sectional Population-based Study +11

Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease

Gopala K. Rangan, Annette Wong, Alexandra Munt et al. · NEJM Evidence · 2021 · 51 citations

Risk of Relapse of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids

Mats Junek, Peter A. Merkel, Eswari Vilayur et al. · Arthritis & Rheumatology · 2024 · 23 citations · Full text